JP2016515141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515141A5 JP2016515141A5 JP2016502876A JP2016502876A JP2016515141A5 JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5 JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016502876 A JP2016502876 A JP 2016502876A JP 2016515141 A5 JP2016515141 A5 JP 2016515141A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- biomarker
- treatment
- pharmaceutical composition
- absence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/072638 WO2014139131A1 (en) | 2013-03-14 | 2013-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| CNPCT/CN2013/072638 | 2013-03-14 | ||
| PCT/US2014/028714 WO2014153018A1 (en) | 2013-03-14 | 2014-03-14 | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Division JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515141A JP2016515141A (ja) | 2016-05-26 |
| JP2016515141A5 true JP2016515141A5 (https=) | 2017-04-06 |
| JP6675300B2 JP6675300B2 (ja) | 2020-04-01 |
Family
ID=51535817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502876A Expired - Fee Related JP6675300B2 (ja) | 2013-03-14 | 2014-03-14 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202804A Pending JP2020040959A (ja) | 2013-03-14 | 2019-11-08 | 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US10442862B2 (https=) |
| JP (2) | JP6675300B2 (https=) |
| WO (2) | WO2014139131A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
| US10484156B2 (en) * | 2016-11-16 | 2019-11-19 | Qualcomm Incorporated | Search space associated with physical downlink control channel based on channel quality indicators |
| JP7113842B2 (ja) * | 2017-03-29 | 2022-08-05 | クラウン バイオサイエンス，インコーポレイテッド（タイツァン） | 胃がんのセツキシマブ感受性を決定するためのシステムおよび方法 |
| EP3635373B1 (en) * | 2017-06-06 | 2025-07-30 | University of Maryland, College Park | Analysis of single cell mechanical phenotyping for metastatic detection |
| CN107582993A (zh) * | 2017-11-10 | 2018-01-16 | 兰志英 | 一种治疗胃癌的药物及其制备方法 |
| JP7493237B2 (ja) * | 2018-11-14 | 2024-05-31 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN113045661B (zh) * | 2021-04-07 | 2022-06-21 | 中美冠科生物技术（太仓）有限公司 | 新型抗cd4抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117553A2 (en) | 2004-05-27 | 2005-12-15 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| CA2636074A1 (en) * | 2006-01-04 | 2007-07-12 | University Of Montpellier 1 | Combination therapy using anti-egfr and anti-her2 antibodies |
| US20090017050A1 (en) * | 2007-07-13 | 2009-01-15 | Ventana Medical Systems, Inc. | Egfr antigen-binding molecules and uses thereof |
| US8583380B2 (en) * | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| US9345767B2 (en) | 2011-05-16 | 2016-05-24 | Taiho Pharmaceutical Co., Ltd. | Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and EGFR inhibitor |
| WO2014139131A1 (en) | 2013-03-14 | 2014-09-18 | Crown Bioscience, Inc. | Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents |
-
2013
- 2013-03-14 WO PCT/CN2013/072638 patent/WO2014139131A1/en not_active Ceased
-
2014
- 2014-03-14 US US14/775,117 patent/US10442862B2/en active Active
- 2014-03-14 JP JP2016502876A patent/JP6675300B2/ja not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/028714 patent/WO2014153018A1/en not_active Ceased
-
2019
- 2019-11-08 JP JP2019202804A patent/JP2020040959A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ajani et al. | Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology | |
| Bell et al. | Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations | |
| Pestana et al. | Histology-agnostic drug development—considering issues beyond the tissue | |
| Ilson et al. | A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus | |
| Carlson et al. | NCCN Task Force Report: adjuvant therapy for breast cancer | |
| Wülfing et al. | A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma | |
| Locati et al. | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact | |
| Prat et al. | Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay | |
| Fuchs et al. | Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab | |
| Stintzing et al. | Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group | |
| JP2016515141A5 (https=) | ||
| Muller et al. | Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma | |
| Wills et al. | Role of liquid biopsies in colorectal cancer | |
| Souche et al. | First and repeat liver resection for primary and recurrent intrahepatic cholangiocarcinoma | |
| Wang et al. | CC motif chemokine ligand 5 (CCL5) levels in gastric cancer patient sera predict occult peritoneal metastasis and a poorer prognosis | |
| Fleischmann et al. | ACO/ARO/AIO-21-Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group | |
| Jin et al. | Differential response to EGFR-and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases | |
| Pandey et al. | Personalized treatment approach for HER2-positive metastatic breast cancer | |
| Shuster et al. | Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer | |
| Kristiansen et al. | Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study | |
| JP7298827B2 (ja) | 抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を予測する方法、がんの悪性度を評価する方法、及び抗ｐｄ－１抗体若しくは抗ｐｄ－ｌ１抗体療法の奏効性を上昇させる方法 | |
| Yamamoto et al. | Prospective observational study of bevacizumab combined with paclitaxel as first-or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study | |
| Akdogan et al. | The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer | |
| JP2019519772A (ja) | Ｈｅｒ２及びｈｅｒ３の経路サブタイピングに基づく乳癌患者の薬物療法の選択方法 | |
| Yonemori et al. | Contrasting prognostic implications of platelet-derived growth factor receptor-β and vascular endothelial growth factor receptor-2 in patients with angiosarcoma |